SCHEMBL4638418

SCHEMBL4638418

CC(=O)c1cccc(-c2c(C)c(C(=O)O)cn2C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 4/20 0.41
AKR1C2 P52895 4/20 0.41
BRD4 O60885 2/20 0.41
BRD2 P25440 1/20 0.41
CREBBP Q92793 1/20 0.41
MAP4K4 O95819 2/20 0.40
CLK4 Q9HAZ1 2/20 0.40
AURKA O14965 1/20 0.40
DAPK3 O43293 1/20 0.40
JAK2 O60674 1/20 0.40
ABL1 P00519 1/20 0.40
NTRK1 P04629 1/20 0.40
CSF1R P07333 1/20 0.40
RET P07949 1/20 0.40
FGFR1 P11362 1/20 0.40
PRKACA P17612 1/20 0.40
KDR P35968 1/20 0.40
MAP2K2 P36507 1/20 0.40
MAPK8 P45983 1/20 0.40
CDK8 P49336 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4638200 0.88 DHODH (0.46) BRD4CSF1R
SCHEMBL4639547 0.80 EPHX2 (0.55) BRD4MAP4K4JAK2RETKDR
SCHEMBL4639232 0.78 XDH (0.52) BRD4TGFBR1
SCHEMBL2556585 0.74 NR1H4 (0.46) AKR1C3AKR1C2BRD4BRD2CREBBP
SCHEMBL4639687 0.73 MYC (0.49) AKR1C3AKR1C2ACLYAKR1B10AKR1B1
SCHEMBL2557549 0.72 FOLH1 (0.52) AKR1C3AKR1C2EIF4EMEN1KMT2A
SCHEMBL4795761 0.72 PTGS2 (0.46) BRD4GSK3BTGFBR1HDAC2NPC1
SCHEMBL10024260 0.72 ACLY (0.49) AKR1C3AKR1C2BRD4BRD2CREBBP
SCHEMBL10024264 0.72 RXRB (0.53) AKR1C3AKR1C2BRD4BRD2CREBBP
SCHEMBL4638916 0.72 NOTUM (0.42) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP disclosed
EP-1844020-B1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS EXELIXIS INC (US) 2017-09-06 EP disclosed
US-8367667-B2 Pyrrole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2013-02-05 US disclosed
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2011-12-08 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP disclosed
EP-1844020-A1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS Exelixis, Inc. (US) 2007-10-17 EP disclosed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP disclosed
WO-2006076202-A1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS EXELIXIS, INC. (US) 2006-07-20 WO disclosed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 AKR1C3 1472/4885AKR1C2 1389/4885BRD4 2050/4885
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 AKR1C3 1472/4885AKR1C2 1389/4885BRD4 2050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.